Proteomic analysis reveals paediatric adrenocortical tumour subtypes

medwireNews: Paediatric adrenocortical tumours (pACT) are a biologically diverse group of diseases that can be divided into clinically distinct subtypes using proteomic profiling, say German researchers.

They report in eBioMedicine that they have identified “four proteome-defined tumour states that only partially overlap with standard histopathological categories”, each with distinct “endocrine activity, proliferation, vascular invasion, necrosis, and survival.”

Furthermore, the investigators say that these pACT subtypes can be distinguished using a “compact five-protein classifier and that each tumour state is associated with distinct, potentially druggable pathways.”

Rainer Claus (University of Augsburg) and co-workers used mass spectrometry-based proteomic profiling to assess 83 pACTs and 43 adjacent non-tumour adrenal cortex samples taken from 72 children. The patients were aged a median of 3.5 years at diagnosis and 69% were girls.

Pathology classified the tumours using Wieneke criteria as adrenocortical carcinomas (ACC, n=42), benign adenomas (ACA, n=25) and neoplasms of uncertain malignant potential (ACX, n=16). Over three-quarters (75%) of the tumours were hormonally active – resulting in virilisation or precocious puberty, Cushing syndrome, or a mixed phenotype, and the remaining 18 tumours were non-functional or of unknown phenotype.

The researchers say there were “profound proteomic differences” between tumours and their adjacent non-tumour adrenal cortex, “characterised by activation of cholesterol biosynthesis, steroidogenic, MYC, mTORC1, and cell-cycle programs”, as well as by the “suppression of extracellular matrix, adhesion and immune-related pathways.”

Analysis identified four proteome-defined tumour states (C1–C4) that only partial overlapped with conventional histopathology classifications. “Rather than a simple linear malignancy continuum across ACA–ACX–ACC, our analyses revealed qualitatively distinct tumour subtypes,” the authors write, with significant differences in endocrine phenotype, vascular invasion, Ki67 index and necrosis, as well as overall survival.

For example, tumour subtype C1 showed features indicating an “enhanced stromal interaction or altered microenvironment composition,” the authors write, whereas C2 and C3 subtypes were metabolically active and had steroidogenic activity in pathways such as cholesterol biosynthesis. The C4 tumor subtype showed a “highly proliferative” state characterised by E2F and MYC activation, and was associated with the poorest patient survival, they say.

These subtype characteristics include vulnerabilities that could point to “distinct therapeutic target landscapes, including [insulin-like growth factor]-axis and epigenetic vulnerabilities,” the team hopes.

Moreover, the authors identified five proteins (DAAM2, CIP2A, TSC2, PALS2, and P3H1) that classified the 83 tumours by subtype with 92.8% accuracy based on the relative abundance of each protein.

“The proposed protein classifier and therapeutic target landscape are not yet ready for routine clinical use and require independent validation,” Claus et al note.

“However, they provide a framework for future studies aiming to develop practical diagnostic tools, refine prognostic assessment, and design biology-informed treatment strategies for children and adolescents with pACT.”

By Lynda Williams

medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2026 Springer Healthcare Ltd, part of Springer Nature

Citation(s)
eBioMedicine 2026; 133: 106504
Sign up for eAlerts
Be the first to hear about new resources and content by signing up to receive our eAlerts.

We'd love your feedback!

Please complete this short 5-question survey to help improve the content offered on this website.
Please rank the following aspects of the program from best [1] to worst [4].